Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

SHSE:600196 Rapporto sulle azioni

Cap. di mercato: CN¥65.1b

Shanghai Fosun Pharmaceutical (Group) Gestione

Gestione criteri di controllo 2/4

Shanghai Fosun Pharmaceutical (Group) Il CEO è Deyong Wen, nominato in Jan2022, e ha un mandato di 2.83 anni. la retribuzione annua totale è CN¥ 10.00M, composta da 25.9% di stipendio e 74.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.004% delle azioni della società, per un valore di CN¥ 2.54M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.1 anni e 3.4 anni.

Informazioni chiave

Deyong Wen

Amministratore delegato

CN¥10.0m

Compenso totale

Percentuale dello stipendio del CEO25.9%
Mandato del CEO2.8yrs
Proprietà del CEO0.004%
Durata media del management2.1yrs
Durata media del Consiglio di amministrazione3.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

There May Be Some Bright Spots In Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Earnings

Nov 05
There May Be Some Bright Spots In Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Earnings

Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Is Paying Out Less In Dividends Than Last Year

Aug 03
Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Is Paying Out Less In Dividends Than Last Year

Here's Why Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Has A Meaningful Debt Burden

Jul 28
Here's Why Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Has A Meaningful Debt Burden

Market Still Lacking Some Conviction On Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196)

May 23
Market Still Lacking Some Conviction On Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

May 01
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next

We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings

Apr 02
We Think You Can Look Beyond Shanghai Fosun Pharmaceutical (Group)'s (SHSE:600196) Lackluster Earnings

Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?

Mar 18
Is Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) A Risky Investment?

Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?

Feb 26
Are Investors Undervaluing Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHSE:600196) By 48%?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Deyong Wen rispetto agli utili di Shanghai Fosun Pharmaceutical (Group)?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

CN¥2b

Jun 30 2024n/an/a

CN¥2b

Mar 31 2024n/an/a

CN¥2b

Dec 31 2023CN¥10mCN¥3m

CN¥2b

Sep 30 2023n/an/a

CN¥4b

Jun 30 2023n/an/a

CN¥4b

Mar 31 2023n/an/a

CN¥4b

Dec 31 2022CN¥8mCN¥2m

CN¥4b

Compensazione vs Mercato: La retribuzione totale di Deyong ($USD 1.38M ) è superiore alla media delle aziende di dimensioni simili nel mercato CN ($USD 264.38K ).

Compensazione vs guadagni: La retribuzione di Deyong è aumentata di oltre il 20%, mentre gli utili aziendali sono diminuiti di oltre il 20% nell'ultimo anno.


AMMINISTRATORE DELEGATO

Deyong Wen (53 yo)

2.8yrs

Mandato

CN¥9,997,000

Compensazione

Mr. Deyong Wen serves as Executive Director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since August 10 2022. He has been a Non-Executive Director at Shanghai Henlius Biotech, Inc. since July 28, 20...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Kexin Wang
Executive Co-Chairman2.9yrsCN¥15.25m0.012%
CN¥ 8.0m
Yifang Wu
Executive Chairman8.3yrsCN¥12.14m0.045%
CN¥ 29.6m
Deyong Wen
Joint President2.8yrsCN¥10.00m0.0039%
CN¥ 2.5m
Xiaohui Guan
Executive Vice Chairman2.9yrsCN¥9.14m0.011%
CN¥ 7.2m
Rongli Feng
Executive President & Chief Human Resources Officeless than a yearNessun dato0.0043%
CN¥ 2.8m
Jing Li
Executive President and CEO of Established Medicines Manufacturing & Supply Divisionno dataNessun dato0.0043%
CN¥ 2.8m
Wang Xingli
Executive President1.8yrsNessun datoNessun dato
Wenjie Zhang
Executive President & Co-CEO of Innovative Drug Division1.8yrsNessun datoNessun dato
Zhanyu Chen
Senior VP & CFOless than a yearNessun datoNessun dato
Jia Yan
Director of the Accounting Departmentno dataNessun datoNessun dato
Dongjiu Li
Senior Vice President & Director of Pharmaceutical Commerce Admin Station Committee3.7yrsNessun dato0.0025%
CN¥ 1.6m
Donghua Wang
Senior VP & Chief Strategic Enabler4.1yrsNessun dato0.0043%
CN¥ 2.8m

2.1yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di 600196 è considerato esperto (durata media dell'incarico 2.1 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Kexin Wang
Executive Co-Chairman2.9yrsCN¥15.25m0.012%
CN¥ 8.0m
Yifang Wu
Executive Chairman8.3yrsCN¥12.14m0.045%
CN¥ 29.6m
Deyong Wen
Joint President2.3yrsCN¥10.00m0.0039%
CN¥ 2.5m
Xiaohui Guan
Executive Vice Chairman2.9yrsCN¥9.14m0.011%
CN¥ 7.2m
Guliang Tang
Independent Non-Executive Director5.4yrsCN¥392.00kNessun dato
Qiyu Chen
Non-Executive Director19.5yrsNessun dato0.0043%
CN¥ 2.8m
Xiaoliang Xu
Non-Executive Director5.4yrsNessun datoNessun dato
Ling Li
Independent Non-Executive Director5.4yrsCN¥392.00kNessun dato
Tze Shan Yu
Independent Non-Executive Director3.4yrsCN¥392.00kNessun dato
Yuqing Chen
Non-Executive Directorless than a yearNessun dato0.0058%
CN¥ 3.8m
Quandi Wang
Independent Non-Executive Director3.4yrsCN¥392.00kNessun dato
Bing Chen
Chief Supervisor1.4yrsNessun datoNessun dato

3.4yrs

Durata media

54yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 600196 sono considerati esperti (durata media dell'incarico 3.4 anni).